Genius AI Detection

K201019

Hologic, Inc. · cleared 2020-11-18 · product code QDQ · Radiology

Premarket evidence — what FDA accepted

Device typesamd
source quote (p.3)
Genius Al Detection is a computer-aided detection and diagnosis (CADe/CADx) software device intended to be used with compatible digital breast tomosynthesis (DBT) systems to identify and mark regions of interest including soft tissue densities (masses, architectural distortions and asymmetries) and calcifications in DBT exams from compatible DBT systems and provide confidence scores that offer assessment for Certainty of Findings and a Case Score. The device intends to aid in the interpretation of digital breast tomosynthesis exams in a concurrent fashion, where the interpreting physician confirms or dismisses the findings during the reading of the exam.
Algorithmdeep learning networks
source quote (p.4)
Genius Al Detection analyzes each standard mammographic view in a digital breast tomosynthesis examination using deep learning networks.
Adaptive (vs locked)FDA source did not state this
PCCPFDA source did not state this
Cybersecurity addressedYes
source quote (p.5)
"Content of Premarket Submissions for Management of Cybersecurity in Medical Devices,” issued on October 2, 2014

Validation studies (2)

Reader study (MRMC)

n=390 cases

endpoints: AUC; sensitivity; recall rate for non-cancer cases; case read-time

Standalone

n=764 cases

endpoints: detection performance; number and type of cancers detected; fROC analysis

Reported performance (3 observations)

sensitivity0.759
source quote (p.10)
The average observed reader sensitivity for cancer cases was 75.9% with CAD and 66.8% without CAD.
aurocas written: “auc0.825CI 95% CI: 0.783, 0.867
source quote (p.9)
The average observed AUC was 0.825 (95% CI: 0.783, 0.867) with CAD and 0.794 (95% CI: 0.748, 0.840) without CAD.
sensitivityas written: “recall rate for non-cancer cases0.258
source quote (p.10)
The average observed recall rate for non-cancer cases was 25.8% with CAD and 23.4% without CAD.

Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.

Predicate network

Postmarket — what happened after clearance

0
recalls in product code, 24mo
0
MAUDE reports in code, 12mo
vs code's own 3-yr baseline
3
drift signals on this device
  • re_clearance

    The FDA AI/ML device list shows a newer 510(k) K243341 (decision 2025-07-31) from Hologic, Inc. for a matching device line ("Genius AI Detection 2.0") — a new clearance for the same line is a change event.

    first seen 2026-07-08 · k_number:K243341

  • re_clearance

    The FDA AI/ML device list shows a newer 510(k) K230096 (decision 2023-05-23) from Hologic, Inc. for a matching device line ("Genius AI Detection 2.0 with CC-MLO Correlation") — a new clearance for the same line is a change event.

    first seen 2026-07-08 · k_number:K230096

  • re_clearance

    The FDA AI/ML device list shows a newer 510(k) K221449 (decision 2022-10-06) from Hologic, Inc. for a matching device line ("Genius AI Detection 2.0") — a new clearance for the same line is a change event.

    first seen 2026-07-08 · k_number:K221449

Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.

Reimbursement — how devices like this got paid

Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).

RIGOR™ Precedent · public FDA/CMS data · descriptive decision-support, not regulatory or reimbursement advice. Share this page: radar.healthai.com/precedent/device/K201019